AP2388A - A group of nucleic acid fragments for prevention of HIV infection or AIDS and the usage thereof. - Google Patents

A group of nucleic acid fragments for prevention of HIV infection or AIDS and the usage thereof.

Info

Publication number
AP2388A
AP2388A AP2005003344A AP2005003344A AP2388A AP 2388 A AP2388 A AP 2388A AP 2005003344 A AP2005003344 A AP 2005003344A AP 2005003344 A AP2005003344 A AP 2005003344A AP 2388 A AP2388 A AP 2388A
Authority
AP
ARIPO
Prior art keywords
aids
usage
prevention
group
nucleic acid
Prior art date
Application number
AP2005003344A
Other languages
English (en)
Other versions
AP2005003344A0 (en
Inventor
Zhiwen Zhou
Yuxia Feng
Conglin Zuo
Original Assignee
Beijing Solobio Genetechnology Compagny Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Solobio Genetechnology Compagny Ltd filed Critical Beijing Solobio Genetechnology Compagny Ltd
Publication of AP2005003344A0 publication Critical patent/AP2005003344A0/xx
Application granted granted Critical
Publication of AP2388A publication Critical patent/AP2388A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AP2005003344A 2002-12-18 2003-12-16 A group of nucleic acid fragments for prevention of HIV infection or AIDS and the usage thereof. AP2388A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB021567859A CN1301263C (zh) 2002-12-18 2002-12-18 一组抗hiv感染及防治艾滋病的核苷酸序列及其应用
PCT/CN2003/001068 WO2004055035A1 (fr) 2002-12-18 2003-12-16 Groupe de fragments d'acide nucleique s'utilisant pour prevenir l'infection par vih ou le sida et utilisation correspondante

Publications (2)

Publication Number Publication Date
AP2005003344A0 AP2005003344A0 (en) 2005-06-30
AP2388A true AP2388A (en) 2012-03-27

Family

ID=32514455

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003344A AP2388A (en) 2002-12-18 2003-12-16 A group of nucleic acid fragments for prevention of HIV infection or AIDS and the usage thereof.

Country Status (12)

Country Link
US (5) US7906641B2 (fr)
EP (5) EP2246357B1 (fr)
JP (4) JP2006516122A (fr)
CN (1) CN1301263C (fr)
AP (1) AP2388A (fr)
AU (1) AU2003292852A1 (fr)
CA (5) CA2808592C (fr)
EA (1) EA009290B1 (fr)
ES (5) ES2394270T3 (fr)
HK (4) HK1150055A1 (fr)
OA (1) OA13148A (fr)
WO (1) WO2004055035A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100395334C (zh) * 2004-08-24 2008-06-18 暨南大学 抑制bcl-2基因表达的siRNA双链
CN1948475B (zh) * 2004-10-13 2010-12-08 厦门大学 可用于治疗艾滋病的重组表达载体、经改造的造血干细胞和方法
CN103316356B (zh) 2012-03-22 2016-08-17 北京三诺佳邑生物技术有限责任公司 一种重组慢病毒载体制剂
WO2016029275A1 (fr) * 2014-08-28 2016-03-03 Newsouth Innovations Pty Limited Traitement du vih
CN114081950B (zh) * 2020-08-24 2023-07-28 深圳市诺瑞博泰生物科技有限公司 Crem/icer基因或其转录体作为靶点在制备抗hiv药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009154A2 (fr) * 1997-08-19 1999-02-25 Hybridon, Inc. Nouveaux oligonucleotides synthetiques specifiques au vih et leurs procedes d'utilisation
WO2003070193A2 (fr) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc Inhibition induite par interference arn de l'expression du gene vih au moyen d'acides nucleiques interferents courts (sina)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US595768A (en) * 1897-12-21 And clarence ran
DK0806484T3 (da) * 1989-06-02 2006-08-14 Pasteur Institut Syntese af proteiner eller polypeptider kodet af en nucleotidsekvens af HIV-1, HIV-2 eller SIV.
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
WO1993023574A1 (fr) * 1992-05-14 1993-11-25 Kozal Michael J Procedes d'amplification enzymatique utilises dans le controle de therapies antivirales
WO1995004818A1 (fr) * 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Procede et reactif servant a inhiber la replication du virus de l'immunodeficience humaine
WO1997007808A1 (fr) * 1995-08-25 1997-03-06 The Regents Of The University Of California Agents antiviraux chimers incorporant des acides nucleiques se liant a rev
US6071743A (en) * 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO1998059074A1 (fr) * 1997-06-23 1998-12-30 Emory University Virus de l'immunodeficience humaine induisant le sida chez un primate non humain
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP3351773B2 (ja) * 1999-06-15 2002-12-03 学校法人慶應義塾 Ｈｉｖ−１のサブタイプ決定法
US7098030B2 (en) * 1999-12-31 2006-08-29 Mirus Bio Corporation Polyampholytes for delivering polyions to a cell
US6506596B2 (en) * 2000-06-01 2003-01-14 Anna-Lena Spetz-Holmgren Method of DNA transfer
CZ308053B6 (cs) * 2000-12-01 2019-11-27 Max Planck Gesellschaft Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
AU2002361797A1 (en) * 2001-12-19 2003-07-09 The Regents Of The University Of California Cell lines with latent immunodeficiency virus and methods of use thereof
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009154A2 (fr) * 1997-08-19 1999-02-25 Hybridon, Inc. Nouveaux oligonucleotides synthetiques specifiques au vih et leurs procedes d'utilisation
WO2003070193A2 (fr) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc Inhibition induite par interference arn de l'expression du gene vih au moyen d'acides nucleiques interferents courts (sina)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAPODICI J *
JACQUE J-M ET AL *
PARK WEE-SUNG ET AL *
YAMAMOTO T ET AL *

Also Published As

Publication number Publication date
US20060217326A1 (en) 2006-09-28
CA2808190C (fr) 2015-09-15
US8263761B2 (en) 2012-09-11
US8383804B2 (en) 2013-02-26
ES2394723T3 (es) 2013-02-05
OA13148A (en) 2006-12-13
EP1584623B1 (fr) 2012-08-22
EP2246358A1 (fr) 2010-11-03
US20110217361A1 (en) 2011-09-08
EA200500873A1 (ru) 2006-08-25
CA2808592A1 (fr) 2004-07-01
HK1150055A1 (en) 2011-10-28
CA2808592C (fr) 2015-04-28
CN1301263C (zh) 2007-02-21
ES2394270T3 (es) 2013-01-30
HK1151294A1 (en) 2012-01-27
EP2246357A1 (fr) 2010-11-03
ES2396371T3 (es) 2013-02-21
US8283462B2 (en) 2012-10-09
CA2808318A1 (fr) 2004-07-01
CA2808584C (fr) 2015-04-14
US20110117188A1 (en) 2011-05-19
US20110217362A1 (en) 2011-09-08
JP2011016822A (ja) 2011-01-27
AU2003292852A1 (en) 2004-07-09
AP2005003344A0 (en) 2005-06-30
EP1584623A1 (fr) 2005-10-12
EA009290B1 (ru) 2007-12-28
ES2393870T3 (es) 2012-12-28
JP2006516122A (ja) 2006-06-22
JP2011036250A (ja) 2011-02-24
EP2266995B1 (fr) 2012-09-19
JP2011015692A (ja) 2011-01-27
CN1508141A (zh) 2004-06-30
EP2243786B1 (fr) 2012-08-22
WO2004055035A1 (fr) 2004-07-01
ES2395334T3 (es) 2013-02-12
EP2266995A1 (fr) 2010-12-29
CA2509827C (fr) 2013-05-14
US20110189264A1 (en) 2011-08-04
US8779113B2 (en) 2014-07-15
EP2246357B1 (fr) 2012-08-29
EP2246358B1 (fr) 2012-07-25
CA2808318C (fr) 2015-04-28
CA2808190A1 (fr) 2004-07-01
US7906641B2 (en) 2011-03-15
EP2243786A1 (fr) 2010-10-27
EP1584623A4 (fr) 2007-11-28
HK1151029A1 (en) 2012-01-20
CA2808584A1 (fr) 2004-07-01
CA2509827A1 (fr) 2004-07-01
HK1150449A1 (en) 2011-12-30

Similar Documents

Publication Publication Date Title
IL222761A0 (en) Viral polymerase inhibitors
AP2005003366A0 (en) Pyrimidine derivatives for the prevention of HIV infection.
AU2001272258A1 (en) Viral polymerase inhibitors
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003220249A1 (en) Improved nucleic acid amplification
AU2003301850A1 (en) Hiv vaccine
AP2388A (en) A group of nucleic acid fragments for prevention of HIV infection or AIDS and the usage thereof.
AU2003900064A0 (en) A method of treatment or prophylaxis of viral infection.
EP1447083A4 (fr) Remedes prophylactiques et curatifs contre les infections virales
AU2002366435A1 (en) Nucleic acid amplification
AU2002343043A1 (en) Processing nucleic acid
AU2003295163A1 (en) Composition for the treatment of hiv or aids
AU2002952817A0 (en) Method for the detection of newly acquired hiv infection
AU2002360523A1 (en) Compounds to treat hiv infection and aids
AU2002314274A1 (en) Vaccination against the feline immunodeficiency virus
AU2003235205A1 (en) Preventives for hiv infection
AU2002347346A1 (en) Dna vaccine
AU2002319311A1 (en) Universal stacker
AU2002310591A1 (en) Interferon-alpha induced gene
EP1693058A4 (fr) Agent et mesures pour la prevention d'une infection virale
AP2006003576A0 (en) Entry inhibitors of the HIV virus.
GB0130982D0 (en) Nucleic acid amplification
GB0100288D0 (en) Virus strains
GB0100430D0 (en) Virus strains